Deciphera Pharmaceuticals, a Waltham cancer biotech, said Monday it will be bought by Ono Pharmaceutical for $2.4 billon to expand the Japanese firm’s oncology portfolio and spur its growth in ...

Deciphera Pharmaceuticals Inc. said Monday it has agreed to be acquired by Japan’s Ono Pharmaceutical Co. Ltd in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono will ...

The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono.

Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (GIST) therapy Qinlock.

Deciphera's sales of Qinlock in its current fourth-line use are modest at around the $20 million mark for each of the last three third quarters, which analysts have suggested could be around its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Deciphera in late 2008 signed an 18-month lease for 7,700 square feet of laboratory space owned by Kansas University at Bob Billings Parkway and Wakarusa Drive, near its operations at 4950 ...

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...

AstraZeneca is buying out its roxadustat partner FibroGen in China. Ono Pharmaceutical's $2.4 billion Deciphera acquisition has borne fruit. And more. 1. Novo Nordisk to sue KBP Biosciences over ...